Brief: Quantum Genomics Reaches Firibastat Development Milestone
12/06/2019 17:09
June 12 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* A KEY MILESTONE REACHED BY QUANTUM GENOMICS IN DEVELOPMENT
OF
FIRIBASTAT
* A NOVEL 500 MG CONTROLLED-RELEASE TABLET OF FIRIBASTAT
OFFERING
AN OPTIMAL PHARMACOKINETIC PROFILE FOR ONCE-A-DAY DOSING HAS
BEEN IDENTIFIED
* THE SELECTED TABLET FORMULATION AND THE DOSE OF FIRIBASTAT
WERE
SAFE AND WELL-TOLERATED
Source text for Eikon: urn:newsml:reuters.com:*:nACT58814
Further company coverage: ALQGC.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study